Management of gastric polyps: An endoscopy-based approach

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 11, 2013, Pages 1374-1384

  Shaib, Yasser H ^a   Rugge, Massimo ^b   Graham, David Y ^a   Genta, Robert M ^c,d  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c MIRACA LIFE SCIENCES   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ECL; EGD; Endoscopic Management; Gastric Polyps; GIST; OLGA; PPI

Indexed keywords

NETAZEPIDE; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR;

ADENOMA; ARTICLE; ATROPHIC GASTRITIS; CANCER INCIDENCE; CANCER THERAPY; CARCINOID; CLINICAL EVALUATION; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FOLLOW UP; GASTRITIS; GASTROENTEROLOGY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL STROMAL TUMOR; GASTROSCOPY; HELICOBACTER INFECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MEDICAL LITERATURE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PRACTICE GUIDELINE; RAISED INTRAEPITHELIAL NEOPLASIA; STOMACH CANCER; STOMACH CARCINOID; STOMACH POLYP;

ECL; EGD; ENDOSCOPIC MANAGEMENT; ENTEROCHROMAFFIN-LIKE; ESOPHAGOGASTRODUODENOSCOPY; GASTRIC POLYPS; GASTROINTESTINAL STROMAL TUMORS; GIST; OLGA; OPERATIVE LINK FOR GASTRITIS ASSESSMENT; PPI; PROTON PUMP INHIBITOR;

ENDOSCOPY, DIGESTIVE SYSTEM; HUMANS; POLYPS; STOMACH NEOPLASMS;

EID: 84885868669     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.03.019     Document Type: Article

References (83)

1. Carmack S.W., Genta R.M., Schuler C.M., et al. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009, 104:1524-1532.
2. Omori T., Kamiya Y., Tahara T., et al. Correlation between magnifying narrow band imaging and histopathology in gastric protruding/or polypoid lesions: a pilot feasibility trial. BMC Gastroenterol 2012, 12:17.
3. Elster K. Histologic classification of gastric polyps. Curr Top Pathol 1976, 63:77-93.
4. el-Zimaity H.M., Jackson F.W., Graham D.Y. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997, 92:1858-1860.
5. Raghunath A.S., O'Morain C., McLoughlin R.C. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005, 22(Suppl 1):55-63.
6. Carmack S.W., Genta R.M., Graham D.Y., et al. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol 2009, 6:331-341.
7. Bertoni G., Sassatelli R., Nigrisoli E., et al. Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis. Ital J Gastroenterol Hepatol 1999, 31:192-197.
8. Bianchi L.K., Burke C.A., Bennett A.E., et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008, 6:180-185.
9. Attard T.M., Cuffari C., Tajouri T., et al. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol 2004, 99:681-686.
10. Domizio P., Talbot I.C., Spigelman A.D., et al. Upper gastrointestinal pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. J Clin Pathol 1990, 43:738-743.
11. Genta R.M., Schuler C.M., Robiou C.I., et al. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin Gastroenterol Hepatol 2009, 7:849-854.
12. Kim J.S., Chae H.S., Kim H.K., et al. [Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with omeprazole]. Korean J Gastroenterol 2008, 51:305-308.
13. Hongo M., Fujimoto K. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol 2010, 45:618-624. Gastric Polyps Study Group.
14. Jianu C.S., Fossmark R., Viset T., et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012, 36:644-649.
15. Jianu C.S., Lange O.J., Viset T., et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012, 47:64-67.
16. Fossmark R., Jianu C.S., Martinsen T.C., et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008, 43:20-24.
17. Abraham N.S. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012, 28:615-620.
18. Bajaj J.S., Ratliff S.M., Heuman D.M., et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 2012, 36:866-874.
19. Juel J., Pareek M., Jensen S.E. The clopidogrel-PPI interaction: an updated mini-review. Curr Vasc Pharmacol 2012, Epub ahead of print.
20. Rotramel A., Poritz L.S., Messaris E., et al. PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. J Gastrointest Surg 2012, 16:2267-2273.
21. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink?. Drugs 2012, 72:437-445.
22. Lau Y.T., Ahmed N.N. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 2012, 32:67-79.
23. Dirschmid K., Platz-Baudin C., Stolte M. Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa?. Virchows Arch 2006, 448:80-84.
24. Archimandritis A., Spiliadis C., Tzivras M., et al. Gastric epithelial polyps: a retrospective endoscopic study of 12974 symptomatic patients. Ital J Gastroenterol 1996, 28:387-390.
25. Abraham S.C., Singh V.K., Yardley J.H., et al. Hyperplastic polyps of the stomach: associations with histologic patterns of gastritis and gastric atrophy. Am J Surg Pathol 2001, 25:500-507.
26. Cerwenka H., Bacher H., Mischinger H.J. Pyloric obstruction caused by prolapse of a hyperplastic gastric polyp. Hepatogastroenterology 2002, 49:958-960.
27. Chen H.W., Lu C.H., Shun C.T., et al. Gastric outlet obstruction due to giant hyperplastic gastric polyps. J Formos Med Assoc 2005, 104:852-855.
28. Dixon M.F., O'Connor H.J., Axon A.T., et al. Reflux gastritis: distinct histopathological entity?. J Clin Pathol 1986, 39:524-530.
29. Maguilnik I., Neumann W.L., Sonnenberg A., et al. Reactive gastropathy is associated with inflammatory conditions throughout the gastrointestinal tract. Aliment Pharmacol Ther 2012, 36:736-743.
30. Lauwers G.Y., Wahl S.J., Melamed J., et al. p53 expression in precancerous gastric lesions: an immunohistochemical study of PAb 1801 monoclonal antibody on adenomatous and hyperplastic gastric polyps. Am J Gastroenterol 1993, 88:1916-1919.
31. Nogueira A.M., Carneiro F., Seruca R., et al. Microsatellite instability in hyperplastic and adenomatous polyps of the stomach. Cancer 1999, 86:1649-1656.
32. Murakami K., Mitomi H., Yamashita K., et al. p53, but not c-Ki-ras, mutation and down-regulation of p21WAF1/CIP1 and cyclin D1 are associated with malignant transformation in gastric hyperplastic polyps. Am J Clin Pathol 2001, 115:224-234.
33. Yao T., Kajiwara M., Kuroiwa S., et al. Malignant transformation of gastric hyperplastic polyps: alteration of phenotypes, proliferative activity, and p53 expression. Hum Pathol 2002, 33:1016-1022.
34. Hattori T. Morphological range of hyperplastic polyps and carcinomas arising in hyperplastic polyps of the stomach. J Clin Pathol 1985, 38:622-630.
35. Zea-Iriarte W.L., Sekine I., Itsuno M., et al. Carcinoma in gastric hyperplastic polyps. A phenotypic study. Dig Dis Sci 1996, 41:377-386.
36. Rugge M., Leandro G., Farinati F., et al. Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer 1995, 76:376-382.
37. Capelle L.G., de Vries A.C., Haringsma J., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010, 71:1150-1158.
38. Rugge M., Meggio A., Pennelli G., et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007, 56:631-636.
39. Dixon M.F., Genta R.M., Yardley J.H., et al. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20:1161-1181.
40. Graham D.Y., Nurgalieva Z.Z., el-Zimaity H.M., et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 2006, 4:306-314.
41. Vilaichone R.K., Mahachai V., Graham D.Y. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am 2006, 35:229-247.
42. Suzuki S., Ohkusa T., Shimoi K., et al. Disappearance of multiple hyperplastic polyps after the eradication of Helicobacter pylori. Gastrointest Endosc 1997, 46:566-568.
43. Ohkusa T., Takashimizu I., Fujiki K., et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann Intern Med 1998, 129:712-715.
44. Lauwers G.Y., Carneiro F., Graham D.Y., et al. Gastric carcinoma. WHO classification of tumors of the digestive system 2010, 48-58. International Agency for Research Against Cancer, Lyon. 4th ed. F.T. Bosman, F. Carneiro, R.H. Hruban (Eds.).
45. Lauwers G.Y., Srivastava A. Gastric preneoplastic lesions and epithelial dysplasia. Gastroenterol Clin North Am 2007, 36:813-829. vi.
46. Stolte M., Sticht T., Eidt S., et al. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy 1994, 26:659-665.
47. Nakamura T., Nakano G. Histopathological classification and malignant change in gastric polyps. J Clin Pathol 1985, 38:754-764.
48. Laxén F., Sipponen P., Ihamäki T., et al. Gastric polyps; their morphological and endoscopical characteristics and relation to gastric carcinoma. Acta Pathol Microbiol Immunol Scand A 1982, 90:221-228.
49. Abraham S.C., Park S.J., Lee J.H., et al. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod Pathol 2003, 16:786-795.
50. Rugge M., Farinati F., Baffa R., et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology 1994, 107:1288-1296.
51. Tan C.B., Zhi W., Shahzad G., et al. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol 2012, 2012:595968.
52. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58.
53. DeMatteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
54. DeMatteo R.P. Nanoneoadjuvant therapy of gastrointestinal stromal tumor (GIST). Ann Surg Oncol 2009, 16:799-800.
55. Demetri G.D., Benjamin R.S., Blanke C.D., et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007, 5(Suppl 2):S1-S29.
56. Miettinen M., Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001, 438:1-12.
57. Miettinen M., Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol 2011, 104:865-873.
58. Kawanowa K., Sakuma Y., Sakurai S., et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006, 37:1527-1535.
59. Hueman M.T., Schulick R.D. Management of gastrointestinal stromal tumors. Surg Clin North Am 2008, 88:599-614. vii.
60. Nilsson B., Sjölund K., Kindblom L.G., et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007, 96:1656-1658.
61. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83.
62. Hasegawa T., Yang P., Kagawa N., et al. CD34 expression by inflammatory fibroid polyps of the stomach. Mod Pathol 1997, 10:451-456.
63. Allibone R.O., Nanson J.K., Anthony P.P. Multiple and recurrent inflammatory fibroid polyps in a Devon family ("Devon polyposis syndrome"): an update. Gut 1992, 33:1004-1005.
64. Pantanowitz L., Antonioli D.A., Pinkus G.S., et al. Inflammatory fibroid polyps of the gastrointestinal tract: evidence for a dendritic cell origin. Am J Surg Pathol 2004, 28:107-114.
65. Schildhaus H.U., Cavlar T., Binot E., et al. Inflammatory fibroid polyps harbour mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene. J Pathol 2008, 216:176-182.
66. Rossi P., Montuori M., Balassone V., et al. Inflammatory fibroid polyp. A case report and review of the literature. Ann Ital Chir 2012, 83:347-351.
67. Matsushita M., Okazaki K. Atypical EUS features of gastric inflammatory fibroid polyps. Gastrointest Endosc 2005, 61:637-638.
68. Matsushita M., Takakuwa H., Nishio A. Characteristic endosonographic features of gastric inflammatory fibroid polyps. Endoscopy 2001, 33:729-730.
69. Matsushita M., Hajiro K., Okazaki K., et al. Endoscopic features of gastric inflammatory fibroid polyps. Am J Gastroenterol 1996, 91:1595-1598.
70. Klöppel G., Perren A., Heitz P.U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004, 1014:13-27.
71. Solcia E., Arnold R., Capella C., et al. Neuroendocrine neoplasms of the stomach. WHO classification of tumors of the digestive system 2010, 64-68. International Agency for Research Against Cancer, Lyon. 4th ed. F.T. Bosman, F. Carneiro, R.H. Hruban (Eds.).
72. Solcia E., Rindi G., Paolotti D., et al. Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors. Yale J Biol Med 1998, 71:285-290.
73. Rindi G., Bordi C., Rappel S., et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996, 20:168-172.
74. Solcia E., Fiocca R., Villani L., et al. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterol Suppl 1991, 180:146-159.
75. von Rosenvinge E.C., Wank S.A., Lim R.M. Gastric masses in multiple endocrine neoplasia type I-associated Zollinger-Ellison syndrome. Gastroenterology 2009, 137:1222, 537.
76. Kulke M.H., Anthony L.B., Bushnell D.L., et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010, 39:735-752.
77. Kulke M.H., Chan J.A., Meyerhardt J.A., et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 2011, 68:293-300.
78. Rindi G., Azzoni C., La Rosa S., et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999, 116:532-542.
79. Borch K., Ahrén B., Ahlman H., et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005, 242:64-73.
80. Fossmark R., Sørdal O., Jianu C.S., et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012, 36:1067-1075.
81. Muehldorfer S.M., Stolte M., Martus P., et al. Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: a prospective multicentre study. Gut 2002, 50:465-470.
82. Dinis-Ribeiro M., Areia M., de Vries A.C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012, 44:74-94.
83. Rugge M., Cassaro M., Di Mario F., et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003, 52:1111-1116.